0 273

Cited 0 times in

A prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers

DC FieldValueLanguage
dc.contributor.author성진실-
dc.contributor.author이은정-
dc.contributor.author최진현-
dc.contributor.author이은정-
dc.contributor.author최진현-
dc.contributor.author성진실-
dc.contributor.author이은정-
dc.contributor.author최진현-
dc.date.accessioned2019-03-15T02:34:23Z-
dc.date.available2019-03-15T02:34:23Z-
dc.date.issued2019-
dc.identifier.issn0449-3060-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/167578-
dc.description.abstractWe investigated the efficacy of combined radiotherapy (RT) and zoledronic acid in treating painful bone metastases from gastrointestinal cancers. Sixty patients were prospectively enrolled between November 2014 and July 2016. The most common primary cancer type was hepatocellular carcinoma (HCC, n = 25), followed by colorectal cancer (n = 6). Patients received external beam RT of 30-54 Gy in 10-17 fractions or 20 Gy in 5 fractions for symptomatic bone metastases. On the first day of RT, patients received 4 mg intravenous zoledronic acid, which was repeated monthly for a total of six cycles. The mean pain score before treatment was 6.7, and it decreased to 2.8 at 1 month and 2.1 at 3 months (P < 0.001).The overall pain response rates at 1 and 3 months were 95% and 96%, respectively. Among the 24 patients who underwent magnetic resonance imaging, 71% were responders, with a complete response in 1 patient and partial in 16 patients. Combined treatment significantly decreased levels of macrophage inflammatory protein-1α and matrix metalloproteinase (MMP)-2 and -3 compared with baseline (all P < 0.05). In HCC patients, IL-6 and MMP-9 levels were significantly lower 1 month after treatment (P < 0.05). The mean quality of life (QOL) score improved from 66 to 56 at 1 month (P < 0.001) and 55 at 3 months (P = 0.016). The median survival was 7 months. In conclusion, RT with zoledronic acid decreased bone pain and improved QOL in patients with painful bone metastases from gastrointestinal cancers. Radiographic findings and serum biomarker measurements were closely correlated with therapeutic responses.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherOxford University Press-
dc.relation.isPartOfJOURNAL OF RADIATION RESEARCH-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleA prospective Phase II study for the efficacy of radiotherapy in combination with zoledronic acid in treating painful bone metastases from gastrointestinal cancers-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorJinhyun Choi-
dc.contributor.googleauthorEun Jung Lee-
dc.contributor.googleauthorSeung Hyun Yang-
dc.contributor.googleauthorYoo Ri Im-
dc.contributor.googleauthorJinsil Seong-
dc.identifier.doi10.1093/jrr/rry092-
dc.contributor.localIdA01956-
dc.contributor.localIdA03047-
dc.contributor.localIdA03047-
dc.contributor.localIdA04697-
dc.contributor.localIdA04697-
dc.contributor.localIdA03047-
dc.contributor.localIdA03047-
dc.contributor.localIdA04697-
dc.contributor.localIdA04697-
dc.contributor.localIdA01956-
dc.contributor.localIdA01956-
dc.contributor.localIdA03047-
dc.contributor.localIdA03047-
dc.contributor.localIdA04697-
dc.contributor.localIdA04697-
dc.relation.journalcodeJ01727-
dc.identifier.eissn1349-9157-
dc.identifier.pmid30445597-
dc.identifier.urlhttps://academic.oup.com/jrr/advance-article/doi/10.1093/jrr/rry092/5184952-
dc.subject.keywordbone metastasis-
dc.subject.keywordgastrointestinal cancer-
dc.subject.keywordradiotherapy-
dc.subject.keywordzoledronic acid-
dc.contributor.alternativeNameSeong, Jin Sil-
dc.contributor.affiliatedAuthor성진실-
dc.contributor.affiliatedAuthor이은정-
dc.contributor.affiliatedAuthor이은정-
dc.contributor.affiliatedAuthor최진현-
dc.contributor.affiliatedAuthor최진현-
dc.contributor.affiliatedAuthor이은정-
dc.contributor.affiliatedAuthor이은정-
dc.contributor.affiliatedAuthor최진현-
dc.contributor.affiliatedAuthor최진현-
dc.contributor.affiliatedAuthor성진실-
dc.contributor.affiliatedAuthor성진실-
dc.contributor.affiliatedAuthor이은정-
dc.contributor.affiliatedAuthor이은정-
dc.contributor.affiliatedAuthor최진현-
dc.contributor.affiliatedAuthor최진현-
dc.citation.volume60-
dc.citation.number2-
dc.citation.startPage242-
dc.citation.endPage248-
dc.identifier.bibliographicCitationJOURNAL OF RADIATION RESEARCH, Vol.60(2) : 242-248, 2019-
dc.identifier.rimsid46354-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.